viewAvacta Group PLC

Avacta Group Plc focused on securing third-party deals for both sides of the business

Alastair Smith, chief executive of Avacta Group Plc (LON:AVCT), talks Proactive's Andrew Scott through the latest developments across the business.

Looking ahead, Smith says: ''The priorities for us without doubt are third party deals  on both sides - be they licensing deals, supply deals etc on the reagents and diagnostics side and we've got a really full pipeline of high quality partners evaluating the technology''.

''We have sufficient going on in the pipeline to be confident those deals will start to come through this year and into 2019 and onwards''.

''On the therapeutics side we've got a lot of confidence now we can do deals at a preclinical stage''.

Smith also discusses the appointment of Dr Eliot Forster as non-executive chairman to the board.

Quick facts: Avacta Group PLC

Price: 171 GBX

Market: AIM
Market Cap: £432.03 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avacta Group PLC named herein, including the promotion by the Company of Avacta Group PLC in any Content on the Site, the Company receives from...


Avacta Plc's therapeutics business 'has huge amount of potential' - analyst...

Capital Network analyst Ed Stacey discusses the major value driver for Avacta - the development of its proprietary Affimer technology for therapeutics, particularly in the immune-oncology (I-O) space. The group's reported interim results to January 2019 today, revealing revenues of...

on 9/4/19

2 min read